Latest Breaking News On - ப்ரொஃபெஸர் டேல் ஜெர்டிங் - Page 1 : comparemela.com
Investegate |Destiny Pharma PLC Announcements | Destiny Pharma PLC: Scientific Advisor Gerding chairs C Diff symposium
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
Proactive headlines: e-therapeutics PLC, ZAIM Credit Systems PLC, I3 Energy PLC…
proactiveinvestors.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.co.uk Daily Mail and Mail on Sunday newspapers.
Update on the recently acquired NTCD-M3 programme
Destiny Pharma plc
( Destiny Pharma or the Company )
Update on the recently acquired NTCD-M3 biotherapeutic clinical programme for prevention of recurrence of C. difficileinfections
Brighton, United Kingdom - 22 December 2020: Destiny Pharma plc (AIM: DEST) a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, announces it is making good progress with preparations for the clinical development of NTCD-M3, a Phase 3 ready biotherapeutic for the prevention of C. difficileinfection (CDI) recurrence.
Following the successful fundraising of £10.4 million in November 2020 and completion of the acquisition of NTCD-M3, Destiny Pharma has commenced the work required to prepare for the Phase 3 clinical study that is scheduled to start in 2022.